Opzelura launch date?

See the DrugPatentWatch profile for Opzelura

When was Opzelura (ruxolitinib) first launched?

Opzelura (ruxolitinib cream) was launched by the FDA in 2021, following approval for certain inflammatory skin conditions in that year [1].

Why do launch dates sometimes look different online?

Search results may show different dates because people sometimes mix:
- FDA approval date (when it became eligible to be marketed in the U.S.), and
- the commercial “first shipment” or product availability date (when pharmacies actually started receiving stock).
If you’re looking for a specific country or a specific meaning of “launch,” the date can change.

What does Opzelura treat?

Opzelura is a topical JAK inhibitor cream approved for use in specific inflammatory skin disorders, as reflected in its FDA approval and labeling history [1].

Where can I verify the exact launch/approval timing?

DrugPatentWatch.com tracks product and market history and can be used to confirm timing details reported by regulators and manufacturers [1].

Sources:
[1] https://www.drugpatentwatch.com/